Metagenomic testing detects hidden infections in critically ill children, transforming intensive care diagnostics

Revolutionary Same-Day Testing Transforms Pediatric Intensive Care

A breakthrough diagnostic approach using metagenomic testing is identifying infections that standard methods miss in critically ill children, potentially saving lives and combating antimicrobial resistance. The technology, deployed at Great Ormond Street Hospital in London, sequences all genetic material present in a respiratory sample to detect bacteria, viruses, and fungi simultaneously—a stark contrast to conventional methods that require clinicians to guess which pathogen to test for in advance. During a 2024-25 study involving 122 critically ill children in the pediatric intensive care unit, metagenomic testing identified approximately 90 percent of bacteria and viruses and detected all fungi in samples. Results published in the Lancet Microbe demonstrate the method's clinical impact: in one quarter of cases, the test results directly influenced treatment decisions, including starting, stopping, or changing antibiotics.

A Life-Saving Case Study: Willow's Recovery

Ten-year-old Willow Crowther's case exemplifies the test's potential. In March, she developed pneumonia that triggered seizures and multiple cardiac arrests, leaving her with a 50 percent survival chance when admitted to intensive care. Her mother, Stacey Moore, was prepared for the worst. Metagenomic testing revealed that Willow harbored a drug-resistant bacterial infection requiring a different antibiotic than she had initially received. With proper treatment identified through the test, Willow recovered after several months in hospital and celebrated her tenth birthday in August. Her parents credited the test availability with saving her life, describing the discovery as miraculous given the severity of her condition.

Key Advantages Over Traditional Diagnostics

Metagenomic testing fundamentally reimagines infection detection in ways standard methods cannot match. Traditional bacterial culturing using Petri dishes—technology dating to Victorian times—requires days to grow samples and cannot identify all pathogens. PCR testing can identify viruses and some bacteria but demands advance specification of which organisms to search for, meaning clinicians must make educated guesses that sometimes prove incorrect. Metagenomic analysis bypasses these limitations by examining all genetic material present, enabling simultaneous detection of thousands of potential pathogens from a single sample. The GOSH study identified 50 organisms that routine diagnostics completely missed, suggesting the technology could serve as an early warning system for emerging infectious threats.

Broader Implications and Rollout Plans

The technology is expanding across the National Health Service, with Dr. Julianne Brown, head of the GOSH Metagenomics Service, confirming gradual rollout to approximately 30 intensive care units treating both adults and children across the UK. The project builds on earlier trials at Guy's and St Thomas' NHS Trust, which pioneered metagenomic application for adult respiratory infections. Beyond immediate clinical benefits, the approach carries significance for public health preparedness—officials suggest metagenomic testing could rapidly detect novel pathogens that pose pandemic risks, enabling swift containment measures. Dr. Sam Ray, a consultant in pediatric intensive care at GOSH, emphasized that the test helps "spot infections we would have missed, get children on the right treatment and stop antibiotics when we know they aren't going to work." This last point addresses a critical concern: unnecessary antibiotic use accelerates antimicrobial resistance, a growing global threat that metagenomic precision testing directly combats by enabling clinicians to avoid prescribing drugs that won't help.